CoChat

Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression

Open access
Hu, Tuo, Shukla, Surendra K., Vernucci, Enza, He, Chunbo, Wang, Dezhen, King, Ryan J., Jha, Kanupriya, Siddhanta, Kasturi, Mullen, Nicholas J., Attri, Kuldeep S., Murthy, Divya, Chaika, Nina V., Thakur, Ravi, Mulder, Scott E., Pacheco, Camila G., Fu, Xiao, High, Robin R., Yu, Fang, Lazenby, Audrey, Steegborn, Clemens, Lan, Ping, Mehla, Kamiya, Rotili, Dante, Chaudhary, Sarika, Valente, Sergio, Tafani, Marco, Mai, Antonello, Auwerx, Johan, Verdin, Eric, Tuveson, David, Singh, Pankaj K. · 2021 · Gastroenterology
Cited by 128

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS: SIRT5 plays pleiotropic roles via post-translational modifications, serving as a tumor suppressor, or an oncogene, in different tumors. However, the role SIRT5 plays in the initiation and progression of pancreatic ductal adenocarcinoma (PDAC) remains unknown. METHODS: Published datasets and tissue arrays with SIRT5 staining were used to investigate the clinical relevance of SIRT5 in PDAC. Furthermore, to define the role of SIRT5 in the carcinogenesis of PDAC, we generated autochthonous mouse models with conditional Sirt5 knockout. Moreover, to examine the mechanistic role of SIRT5 in PDAC carcinogenesis, SIRT5 was knocked down in PDAC cell lines and organoids, followed by metabolomics and proteomics studies. A novel SIRT5 activator was used for therapeutic studies in organoids and patient-derived xenografts. RESULTS: SIRT5 expression negatively regulated tumor cell proliferation and correlated with a favorable prognosis in patients with PDAC. Genetic ablation of Sirt5 in PDAC mouse models promoted acinar-to-ductal metaplasia, precursor lesions, and pancreatic tumorigenesis, resulting in poor survival. Mechanistically, SIRT5 loss enhanced glutamine and glutathione metabolism via acetylation-mediated activation of GOT1. A selective SIRT5 activator, MC3138, phenocopied the effects of SIRT5 overexpression and exhibited antitumor effects on human PDAC cells. MC3138 also diminished nucleotide pools, sensitizing human PDAC cell lines, organoids, and patient-derived xenografts to gemcitabine. CONCLUSIONS: Collectively, we identify SIRT5 as a key tumor suppressor in PDAC, whose loss promotes tumorigenesis through increased noncanonic use of glutamine via GOT1, and that SIRT5 activation is a novel therapeutic strategy to target PDAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2021.06.045

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 128

Metadata

Authors
Hu, T., Shukla, S. K., Vernucci, E., He, C., Wang, D., King, R. J., Jha, K., Siddhanta, K., Mullen, N. J., Attri, K. S., Murthy, D., Chaika, N. V., Thakur, R., Mulder, S. E., Pacheco, C. G., Fu, X., High, R. R., Yu, F., Lazenby, A., Steegborn, C., Lan, P., Mehla, K., Rotili, D., Chaudhary, S., Valente, S., Tafani, M., Mai, A., Auwerx, J., Verdin, E., Tuveson, D., & Singh, P. K.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2021-11
Volume
161
Issue
5
Pages
1584-1600
ISSN
0016-5085 (ISSN-L)
OpenAlex
W3179794872
Cited by
128
References
12
FWCI
8.59
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.